Edasalonexent
As of the edition of 20 October 2026, Edasalonexent is a small molecule: stopped in 2020; acts on NFKB1, NFKB2 and RELA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Small molecule
- Registered trials
- 6, 1 stopped early
- Disease areas
- Bones, joints and muscles; Inherited and neonatal; Nervous system; Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 1 | 0 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| BioCryst Pharmaceuticals | Lead sponsor of trials | 2011 to now |